The company said it will start a Phase 2 study of its gene-edited drug candidate for the treatment of cancer. CRSP stock plummets 9.62% in the pre-market to $92.70. For the study, which was conducted on 26 patients, the company gave the drug for 28 days. The results were impressive. After seeing a pop in the regular session, CRSP stock gave back some of its gains in the after-hour. For now, the company is using patient-specific cells. It uses its CRISPR technology to transform them into a customized version of a gene.
Biotech, Tech, and Crypto reporter
Anthony Gonzales brings 3 years of experience in helping grassroots, mid-sized organizations and large institutions strengthen their management and resource generating capacities and effectively plan for the future. He is also a mentor and professional advisor to artists working in all disciplines. He is the gold medalist from St. Marco University of Science and Technology in the Bachelors of Financial Management as well.